http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Ran Zhihua (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Yang Hong,Ran Zhihua,Jin Meng,Qian Jia-Ming 거트앤리버 소화기연관학회협의회 2022 Gut and Liver Vol.16 No.5
Background/Aims: Opportunistic infection in inflammatory bowel disease (IBD) has become a serious problem. However, its status of doctors’ opinions and test equipment in hospitals are unclear. The aim of the study was to investigate these issues to improve the prognosis of IBD patients. Methods: This retrospective, multicenter study was conducted by 83 investigators who were members of the Asian Organization for Crohn’s and Colitis. Data on opportunistic infection were collected from hospital databases between January 2017 and December 2017. The survey consisted of 11 items. Results: Most physicians appreciated the diagnostic value of tissue cytomegalovirus (CMV) DNA, accounting for 86.1% of members in China, 37.5% in Japan, 52.9% in South Korea, and 66.7% in Southeast Asia. Only 83.1% of hospitals had the ability to test for CMV immunohistochemistry in Asia. Hepatitis B surface antigen (HBsAg) screening was recommended by all members. However, only 66.7% in China, 70.6% in South Korea, and 66.7% in Southeast Asia agreed to routinely vaccinate IBD patients when HBsAg tested negative. Most members preferred metronidazole (74.7%) as the first choice for patients with Clostridium difficile infection. However, the proportion of stool C. difficile toxin test was lower in China than in other areas (75.0% in China vs 95.8% in Japan and 100% in South Korea and Southeast Asia, p<0.05). Conclusions: Opportunistic infection from CMV, hepatitis B virus, and C. difficile should be of high concern for IBD patients. More efforts are needed, such as understanding consensus in clinical practice and improving testing facilities in hospitals.
-
( Shaozhong Huang ),( Jiayi Ma ),( Mingming Zhu ),( Zhihua Ran ) 대한장연구학회 2017 Intestinal Research Vol.15 No.1
Background/Aims: Inflammatory bowel disease (IBD) primarily involves the intestinal tract and can affect vitamin absorption. This study was designed to assess the prevalence of vitamin B<sub>12</sub> and folate deficiencies in patients with IBD, and to identify the risk factors associated with abnormal serum vitamin B<sub>12</sub> and folate levels. Methods: We evaluated the medical records of 195 patients with Crohn`s disease (CD) and 62 patients with ulcerative colitis (UC), and selected 118 healthy subjects for the control group. Results: There were more CD patients with vitamin B<sub>12</sub> deficiency than UC patients (14.9% vs. 3.2%, P =0.014) and controls (14.9% vs. 4.2%, P =0.003). The prevalence of folate deficiency was higher in CD patients than in controls (13.3% vs. 3.4%, P =0.004). There were no significant differences in the serum vitamin B<sub>12</sub> and folate statuses of the UC and control groups. Patients with prior ileal or ileocolic resection showed a higher prevalence of abnormal vitamin B<sub>12</sub> levels than those without prior resection (n=6/16, n=23/179; P =0.018). A disease duration within 5 years was a risk factor of abnormal folate levels in CD patients. Conclusions: This study showed that vitamin B<sub>12</sub> and folate deficiencies were more common in patients with CD than in UC patients and controls. Prior ileal or ileocolonic resection was a risk factor of serum vitamin B<sub>12</sub> abnormalities, and a disease duration within 5 years was a risk factor of low serum folate levels in CD patients. (Intest Res 2017;15:103-108)
-
( Chenwen Cai ),( Juntao Lu ),( Lijie Lai ),( Dongjuan Song ),( Jun Shen ),( Jinlu Tong ),( Qing Zheng ),( Kaichun Wu ),( Jiaming Qian ),( Zhihua Ran ) 대한장연구학회 2022 Intestinal Research Vol.20 No.2
Background/Aims: The incidence and prevalence of inflammatory bowel disease (IBD) is rising in Asia recently. The study aimed to obtain a comprehensive understanding of the current status of drug therapy and monitoring for IBD in Asia. Meth ods: A questionnaire investigation on drug therapy and monitoring for IBD was conducted right before the 6th Annual Meeting of Asian Organization for Crohn’s & Colitis. Questionnaires were provided to Asian physicians to fill out via emails between March and May 2018. Results: In total, responses of 166 physicians from 129 medical centers were included for analysis. Among the surveyed regions, the most average number of IBD specialist gastroenterologists and nurses was 4.8 per center in Taiwan and 2.5 per center in Mainland China, respectively. 5-Aminosalicylic acid/sulfasalazine (99.4%) was the most preferred first-line choice for mild-moderate ulcerative colitis (UC), meanwhile corticosteroid (83.7%) was widely applied for severe UC. The first-line medication for Crohn’s disease (CD) markedly varied as corticosteroid (68.1%) was the most favored in Mainland China, Japan, and South Korea, followed by infliximab (52.4%) and azathioprine (47.0%). Step-up strategy was preferred in mild-moderate UC (96.4%), while 51.8% of the physicians selected top-down treatment for CD. Only 25.9% and 17.5% of the physicians could test blood concentration of infliximab and antibody to infliximab in their hospitals, respectively. Conclusions: The current status of drug therapy and monitoring for IBD in Asia possesses commonalities as well as differences. Asian rec ommendations, IBD specialist teams and practice of therapeutic drug monitoring are required to improve IBD management in Asia. (Intest Res 2022;20:213-223)
KCI
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
